Axios @axios
A week after the maker of a controversial Alzheimer's drug announced it would largely stop marketing it, Congress is readying legislation that tinkers with the pathway used by the FDA to approve the drug, but avoids making large-scale changes. https://t.co/1RqERFoaaN — PolitiTweet.org